TR199903257T2 - Ens�lin direncinin b�y�me hormonu sekretagoglar� ile tedavisi. - Google Patents

Ens�lin direncinin b�y�me hormonu sekretagoglar� ile tedavisi.

Info

Publication number
TR199903257T2
TR199903257T2 TR1999/03257T TR9903257T TR199903257T2 TR 199903257 T2 TR199903257 T2 TR 199903257T2 TR 1999/03257 T TR1999/03257 T TR 1999/03257T TR 9903257 T TR9903257 T TR 9903257T TR 199903257 T2 TR199903257 T2 TR 199903257T2
Authority
TR
Turkey
Prior art keywords
growth hormone
treatment
insulin resistance
formula
enriched
Prior art date
Application number
TR1999/03257T
Other languages
English (en)
Turkish (tr)
Inventor
Albert Carpino Philip
Kwok-Fung Chiu Charles
Allen Lefker Bruce
Codetta Pan Lydia
Lee Treadway Judith
Paul Zawistoski Michael
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of TR199903257T2 publication Critical patent/TR199903257T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR1999/03257T 1997-06-25 1998-06-05 Ens�lin direncinin b�y�me hormonu sekretagoglar� ile tedavisi. TR199903257T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5079097P 1997-06-25 1997-06-25

Publications (1)

Publication Number Publication Date
TR199903257T2 true TR199903257T2 (xx) 2000-12-21

Family

ID=21967444

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/03257T TR199903257T2 (xx) 1997-06-25 1998-06-05 Ens�lin direncinin b�y�me hormonu sekretagoglar� ile tedavisi.

Country Status (40)

Country Link
US (3) US6448263B1 (en:Method)
EP (1) EP1000085B1 (en:Method)
JP (2) JP2000514099A (en:Method)
KR (1) KR20010014224A (en:Method)
CN (2) CN1152049C (en:Method)
AP (1) AP1145A (en:Method)
AR (1) AR012256A1 (en:Method)
AT (1) ATE305477T1 (en:Method)
AU (1) AU747510B2 (en:Method)
BG (1) BG104008A (en:Method)
BR (1) BR9810477A (en:Method)
CA (1) CA2294464A1 (en:Method)
CO (1) CO4950621A1 (en:Method)
DE (1) DE69831745T2 (en:Method)
DZ (1) DZ2539A1 (en:Method)
EA (1) EA002089B1 (en:Method)
EG (1) EG21712A (en:Method)
ES (1) ES2248899T3 (en:Method)
HN (1) HN1998000088A (en:Method)
HR (1) HRP980361A2 (en:Method)
HU (1) HUP0001922A3 (en:Method)
ID (1) ID24345A (en:Method)
IL (7) IL154116A0 (en:Method)
IN (1) IN189724B (en:Method)
IS (1) IS5275A (en:Method)
MA (1) MA24581A1 (en:Method)
NO (1) NO996205L (en:Method)
NZ (1) NZ500655A (en:Method)
OA (1) OA11242A (en:Method)
PA (1) PA8452601A1 (en:Method)
PE (1) PE105399A1 (en:Method)
PL (1) PL337659A1 (en:Method)
SK (1) SK175699A3 (en:Method)
TN (1) TNSN98113A1 (en:Method)
TR (1) TR199903257T2 (en:Method)
TW (1) TW553943B (en:Method)
UA (1) UA64751C2 (en:Method)
WO (1) WO1998058949A1 (en:Method)
YU (1) YU70199A (en:Method)
ZA (1) ZA985546B (en:Method)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
US6541634B2 (en) * 1999-02-26 2003-04-01 Pfizer Inc. Process for preparing growth hormone secretagogues
US7721948B1 (en) * 1999-05-25 2010-05-25 Silverbrook Research Pty Ltd Method and system for online payments
EP1132388A3 (en) * 2000-03-09 2004-03-03 Pfizer Products Inc. Hexahydropyrazolo[4,3-c]pyridine metabolites
ATE446758T1 (de) 2000-05-31 2009-11-15 Pfizer Prod Inc Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CN101120138B (zh) * 2004-12-21 2013-06-05 赫尔克里士公司 在含有亚硫酸盐离子的造纸体系中用作干和湿强度剂的活性阳离子树脂
US20070024388A1 (en) * 2005-07-27 2007-02-01 Hassan Tanbakuchi Slabline structure with rotationally offset ground
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US7862825B2 (en) * 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
RU2403902C1 (ru) * 2009-06-15 2010-11-20 Илья Николаевич Медведев Способ снижения биологического возраста при нарушении толерантности к глюкозе
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
CN105164129B (zh) * 2013-05-28 2018-01-19 拉夸里亚创药株式会社 多晶型物形式
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2695649C2 (ru) * 2014-08-05 2019-07-25 Раквалиа Фарма Инк. Производные серина в качестве агонистов грелиновых рецепторов
TW201625613A (zh) * 2014-10-31 2016-07-16 拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
WO2024217441A1 (zh) * 2023-04-21 2024-10-24 长春金赛药业有限责任公司 GHSR 1a激动剂、药物组合物及其制备方法和应用
CN119285632A (zh) * 2024-10-09 2025-01-10 威海中腾医药科技有限公司 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235550A (en) 1966-02-15 Anal g gesiaxoat t tail intravenous injection
US3190802A (en) 1961-10-09 1965-06-22 Boehringer Sohn Ingelheim Shaving composition and method of using same
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
US5242783A (en) 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
CA2147503A1 (en) 1992-11-06 1994-05-26 Judith M. Pisano Substituted dipeptide analogs promote release of growth hormone
WO1994013696A1 (en) 1992-12-11 1994-06-23 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JPH10506091A (ja) 1993-11-09 1998-06-16 メルク エンド カンパニー インコーポレーテッド 成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類
BR9610277A (pt) 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
CZ195098A3 (cs) 1995-12-22 1998-10-14 Novo Nordisk A/S Sloučeniny uvolňující růstový hormon
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
UA64751C2 (uk) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти)
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
AU7445498A (en) * 1997-06-25 1999-01-04 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues

Also Published As

Publication number Publication date
WO1998058949A1 (en) 1998-12-30
SK175699A3 (en) 2001-04-09
AP1145A (en) 2003-02-14
EP1000085B1 (en) 2005-09-28
CN1530107A (zh) 2004-09-22
OA11242A (en) 2003-07-23
JP2005097261A (ja) 2005-04-14
US6448263B1 (en) 2002-09-10
IL133626A0 (en) 2001-04-30
IN189724B (en:Method) 2003-04-19
AU747510B2 (en) 2002-05-16
MA24581A1 (fr) 1998-12-31
DZ2539A1 (fr) 2003-02-08
US6630487B2 (en) 2003-10-07
EA002089B1 (ru) 2001-12-24
EP1000085A1 (en) 2000-05-17
TW553943B (en) 2003-09-21
IL154111A0 (en) 2003-07-31
CN1259140A (zh) 2000-07-05
HRP980361A2 (en) 1999-02-28
EG21712A (en) 2002-02-27
ATE305477T1 (de) 2005-10-15
YU70199A (sh) 2003-01-31
NO996205D0 (no) 1999-12-15
CO4950621A1 (es) 2000-09-01
ES2248899T3 (es) 2006-03-16
IS5275A (is) 1999-11-26
IL154116A0 (en) 2003-07-31
IL154114A0 (en) 2003-07-31
AU7445698A (en) 1999-01-04
PL337659A1 (en) 2000-08-28
AP9801267A0 (en) 1998-06-30
CN1152049C (zh) 2004-06-02
PA8452601A1 (es) 2000-05-24
IL156465A0 (en) 2004-01-04
US20030100561A1 (en) 2003-05-29
TNSN98113A1 (fr) 2005-03-15
BR9810477A (pt) 2007-05-22
JP2000514099A (ja) 2000-10-24
HUP0001922A3 (en) 2001-02-28
NO996205L (no) 1999-12-15
KR20010014224A (ko) 2001-02-26
HN1998000088A (es) 1999-01-08
UA64751C2 (uk) 2004-03-15
HK1028051A1 (en) 2001-02-02
DE69831745T2 (de) 2006-08-31
BG104008A (en) 2000-07-31
ZA985546B (en) 2000-01-10
HUP0001922A2 (hu) 2000-12-28
IL154112A0 (en) 2003-07-31
PE105399A1 (es) 1999-11-04
IL154115A0 (en) 2003-07-31
IL156465A (en) 2004-07-25
CA2294464A1 (en) 1998-12-30
NZ500655A (en) 2002-02-01
EA199901075A1 (ru) 2000-08-28
AR012256A1 (es) 2000-09-27
DE69831745D1 (de) 2006-02-09
ID24345A (id) 2000-07-13
JP3742643B2 (ja) 2006-02-08
US6867202B1 (en) 2005-03-15

Similar Documents

Publication Publication Date Title
TR199903257T2 (xx) Ens�lin direncinin b�y�me hormonu sekretagoglar� ile tedavisi.
TR200100841T2 (tr) Antibiyotiklerin kullanımı
DE60026155D1 (de) Einige alkylendiamin-substituierte heterocyclen
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
TR200100694T2 (tr) Opioid alıcı aktivitesine sahip 4,4-Biarilpiperidin türevleri
CY1107391T1 (el) Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TR200000289T2 (tr) Kimyasal bileşimler
BR0014710A (pt) Métodos para o tratamento de dor
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
TR201900542T4 (tr) Ağrı ve/veya enflamasyon tedavisi için bileşimler.
ES2183351T3 (es) Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EP1664271A4 (en) MODULATION OF THE EXPRESSION OF DIACYLGLYCERIN ACYLTRANSFERASE 2
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
PT1117296E (pt) Combinacao de bisfosfonato e de tetraciclina
DE69840909D1 (de) Analoge von kokain
ATE319440T1 (de) Antidiabetische mittel
WO2002018334A3 (en) Sodium channel modulators
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
DE69506197D1 (de) Verwendung eines Ascorbyl-tocopherylphosphats zur Herstellung eines Arzneimittels zur Behandlung der Pankreatitis
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
PT775745E (pt) Aptameros inibidores de catepsina g